Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fine needle diathermy with or without Avastin for corneal neovascularisation
2015-003180-11Phase 4Terminated
- Sponsor
- University of Nottingham
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bevacizumab in corneal neovascularization (CNV) (2 arms), sponsored by University of Nottingham. Primary endpoint: Decreased corneal neovascularisation. Started Jul 2019; status: terminated.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2015-003180-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003180-11.